Madrigal Pharmaceuticals inc. Stock
Pros and Cons of Madrigal Pharmaceuticals inc. in the next few years
Pros
Cons
Performance of Madrigal Pharmaceuticals inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals inc. | 4.550% | 0.078% | -22.633% | -32.420% | -9.532% | 67.763% | 96.033% |
| Ardelyx Inc. | 3.240% | -0.366% | -11.361% | 47.951% | 3.668% | -1.770% | - |
| Salarius Pharmaceuticals Inc. | -2.830% | -3.738% | -2.830% | -71.389% | -25.766% | -98.474% | -99.994% |
| Brainstorm Cell | 6.550% | -29.447% | -33.143% | -87.283% | 51.293% | -87.897% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Navigating through the financial landscape of Madrigal Pharmaceuticals certainly makes for an intriguing journey. Initial impressions of the company's financials signal some telling red flags but also present a landscape ripe with potential, reflecting the classic high-risk, high-reward scenario often seen in the biotechnology and medical research industry.
A high-level glance at Madrigal Pharmaceuticals' financials reveals a company that has yet to generate revenue, as indicated by the total revenue figure standing at zero across the provided financial statements. This isn't atypical for firms within this sector which often spend considerable time in the research and development (R&D) phase before bringing a product to market.
The balance sheets over the past three years display a robust increase in total assets, most notably in cash reserves. Notwithstanding, the company's net tangible assets remained fairly consistent thanks to a parallel rise in total liabilities.